Madeleine Cochrane

Madeleine Cochrane

Auto-generated profile, based on publicly available information

Madeleine Cochrane

Bristol Medical School, University of Bristol, Bristol, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Applied Health Economics and Health Policy
Verified
Journal Article
Closed access
PDF file
MCM. Cochrane
M. Cochrane
EMEileen Mitchell
Eileen Mitchell
WHW. Hollingworth
W. Hollingworth
ECE. Crawley
E. Crawley
DTDominic Trépel
Dominic Trépel

15 June 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PBPam Ten Broeke
Pam Ten Broeke
MOMerlijn Olthof
Merlijn Olthof
DBDebby G. J. Beckers
Debby G. J. Beckers
NHNicola D. Hopkins
Nicola D. Hopkins
LGLee Graves
Lee Graves
EBErik Bijleveld
Erik Bijleveld
Sitting for prolonged periods of time impairs people’s health. Prior research has mainly investigated sitting behavior on an aggregate level, for example, by analyzing total sitting time per day. By contrast, taking a dynamic approach, here we conceptualize sitting behavior as a continuous chain of sit-to-stand and stand-to-sit transitions. We use multilevel time-to-event analysis to analyze the timing of these transitions. We analyze ∼30,000 objectively measured posture transitions from 156 people during work time. Results indicate that the temporal dynamics of sit-to-stand transitions differ from stand-to-sit transitions, and that people are quicker to switch postures later in the workday, and quicker to stand up after having been more active in the recent hours. We found no evidence for associations with physical fitness. Altogether, these findings provide insights into the origins of people’s stand-up and sit-down decisions, show that sitting behavior is fundamentally different from exercise behavior, and provide pointers for the development of interventions.

1 July 2019 in Social Science & Medicine
Verified
Journal Article
Closed access
MCM. Cochrane
M. Cochrane
PWP.M. Watson
P.M. Watson
HTH. Timpson
H. Timpson
AHA. Haycox
A. Haycox
BCB. Collins
B. Collins
LGLee Graves
Lee Graves

24 July 2018 in International Journal of Mental Health and Addiction
Verified
Journal Article
Open access
PDF file
RHRebecca Harrison
Rebecca Harrison
MHMarie Claire Van Hout
Marie Claire Van Hout
MCMadeleine Cochrane
Madeleine Cochrane
LELindsay Eckley
Lindsay Eckley
RNRobert Noonan
Robert Noonan
HSHarry Sumnall
Harry Sumnall
Contemporary recovery-models of treatment for substance misuse prioritise community-based support systems that focus on developing individuals’ strengths and quality of life. The research project aimed to explore the perceived mechanisms and processes that underpinned support in three abstinence-based recovery communities (RCs) across England. Focus groups and telephone interviews were conducted with 44 individuals. This was to identify self-prioritised outcomes for members and other key factors contributing to the delivery of an effective recovery community. Data were thematically analysed. Along with a number of other key outcomes, the achievement and maintenance of abstinence by participants was considered to be a key indicator of an effective RC. RC processes were also viewed as underpinning the development of recovery capital. The study provides an insight into the processes of RCs and highlights that development and support of recovery capital is an important aspect of service provision and delivery for those in abstinence-based recovery.

30 January 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
MCMadeleine Cochrane
Madeleine Cochrane
MDMarcus J Drake
Marcus J Drake
JWJo Worthington
Jo Worthington
JFJessica Frost
Jessica Frost
NCNikki Cotterill
Nikki Cotterill
SNSian Noble
Sian Noble
Objectives To estimate the cost-effectiveness of a primary care intervention for male lower urinary tract symptoms (LUTS) compared with usual care. Design Economic evaluation alongside a cluster randomised controlled trial from a UK National Health Service (NHS) perspective with a 12-month time horizon. Setting Thirty NHS general practice sites in England. Participants 1077 men aged 18 or older identified in primary care with bothersome LUTS. Interventions A standardised and manualised intervention for the treatment of bothersome LUTS was compared with usual care. The intervention group (n=524) received a standardised information booklet with guidance on conservative treatment for LUTS, urinary symptom assessment and follow-up contacts for 12 weeks. The usual care group (n=553) followed local guidelines between general practice sites. Measures Resource use was obtained from electronic health records, trial staff and participants, and valued using UK reference costs. Quality-adjusted life-years (QALYs) were calculated from the EQ-5D-5L questionnaire. Adjusted mean differences in costs and QALYs and incremental net monetary benefit were estimated. Results 866 of 1077 (80.4%) participants had complete data and were included in the base-case analysis. Over the 12-month follow-up period, intervention and usual care arms had similar mean adjusted costs and QALYs. Mean differences were lower in the intervention arm for adjusted costs −£29.99 (95% CI −£109.84 to £22.63) while higher in the intervention arm for adjusted QALYs 0.001 (95% CI −0.011 to 0.014). The incremental net monetary benefit statistic was £48.01 (95% CI −£225.83 to £321.85) at the National Institute for Health and Care Excellence UK threshold of £20 000 per QALY. The cost-effectiveness acceptability curve showed a 63% probability of the intervention arm being cost-effective at this threshold. Conclusions Costs and QALYs were similar between the two arms at 12 months follow-up. This indicates that the intervention can be implemented in general practice at neutral cost. Trial registration number ISRCTN11669964.

1 July 2025 in Health Technology Assessment
Verified
Journal Article
Open access
MCMadeleine Clout
Madeleine Clout
ALAmanda L Lewis
Amanda L Lewis
MCMadeleine Cochrane
Madeleine Cochrane
GYGrace J Young
Grace J Young
PAPaul Abrams
Paul Abrams
MDMarcus Drake
Marcus Drake
Background: Lower urinary tract symptoms are common in older men and can be bothersome, leading to treatment. The UPSTREAM randomised controlled trial (Phase I) investigated whether assessment of these symptoms with invasive urodynamic testing could improve symptoms when guiding treatment options. Objective: To assess the long-term lower urinary tract symptoms and the rates of surgery for bladder outlet obstruction in men participating in the UPSTREAM study (Phase I). Design: Pragmatic, multicentre, parallel-group, two-group open randomised controlled study, with outcome assessors blinded to aggregate data. Setting: Urology departments of 26 National Health Service hospitals in England. Participants: Men ≥ 18 years, seeking further treatment for their bothersome lower urinary tract symptoms, which may include surgery, who were existing participants of the UPSTREAM study (Phase I). Men were excluded if they were unable to pass urine without a catheter, had a relevant neurological disease, were currently undergoing treatment for prostate or bladder cancer, had previous prostate surgery or were unfit for surgery. Interventions: Routine care plus invasive urodynamics (intervention) or non-invasive routine care. Main outcome measures: The primary outcome was a patient-reported International Prostate Symptom Score 5 years post randomisation. Rates of surgery was the key secondary outcome. Patient-reported outcomes included measures of lower urinary tract symptoms, sexual function, overall quality of life and cost-effectiveness from a secondary care perspective. Data sources: Questionnaires to participants for patient-reported outcome measures, and National Health Service England Hospital Episode Statistics and mortality data. Results: Of 820 men randomised in UPSTREAM (Phase I) between October 2014 and December 2016, 211/427 men randomised to the intervention group completed Phase II questionnaires (49.4%) and 205/363 in the routine care group (56.5%). There was no difference found between International Prostate Symptom Scores in the two groups at 5 years (adjusted difference 0.41, 95% confidence interval −1.10 to 1.93). There was also no difference in other lower urinary tract symptoms, sexual function or quality of life. Routine data were received for 98% of men. Three hundred and forty-seven (43.3%) men with routine data available had received at least one related surgical procedure for the treatment of lower urinary tract symptoms. Over the 5-year time horizon, incremental mean costs were slightly higher (£176.63, 95% confidence interval −£464.06 to £817.32) in the intervention group and incremental mean QALYs were slightly lower (−0.039, 95% confidence interval −0.152 to 0.073) in the intervention group. This suggests that routine care is the cost-effective option. Limitations: Around half of the men from Phase I study completed questionnaires at 5 years, although their characteristics were similar to those of non-responders, withdrawn participants or those who had died. The majority of men were of white ethnicity, so results may be less applicable to other ethnicities. Conclusions: Five-year follow-up does not support the introduction of invasive urodynamics in reducing lower urinary tract symptoms or rates of prostate surgery, from a clinical or cost-effectiveness perspective. Future work: This should identify if there are subgroups of patients who might benefit from the addition of urodynamics to routine care for bothersome lower urinary tract symptoms. Trial registration: This trial is registered as ISRCTN56164274. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 12/140/01) and is published in full in Health Technology Assessment; Vol. 29, No. 26. See the NIHR Funding and Awards website for further award information.